Altimmune to Participate in Two Upcoming Investor Conferences

About this update from Altimmune, Inc.

[{"type":"image","alt":"Altimmune, Inc","displaySize":"","headline":null,"caption":"Altimmune, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gY.Kxe7ML79dI0xW5370RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009","width":150,"height":82}},"lazy":false},{"type":"text","content":"GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences:","length":374,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Stifel 2025 Healthcare ConferenceWednesday, November 12, 2025Fireside Chat at 10:00 a.m. ET","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":93,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Jefferies Global Healthcare ConferenceThursday, November 20, 2025Fireside Chat at 9:30 a.m. GMT","length":97,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":97,"olType":false},{"type":"text","content":"The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.","length":105,"tagName":"p"},{"type":"text","content":"About Altimmune","length":15,"tagName":"p"},{"type":"text","content":"Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.","length":445,"tagName":"p"},{"type":"text","content":"Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on X","length":61,"tagName":"p"},{"type":"text","content":"Investor Contact:Lee RothBurns McClellanPhone: [email protected]","leng...

More updates from Altimmune, Inc.